Effect of haloperidol on transient outward potassium current in rat ventricular myocytes

European Journal of Pharmacology

Volumn 550, Issue 1-3, 2006, Pages 15-23

  Bébarová, Markéta ^a   Matejovič, Peter ^a   Pásek, Michal ^a,b   Nováková, Marie ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF THERMOMECHANICS   (Czech Republic)

Author keywords

Haloperidol; Quantitative model; Rat ventricular myocytes; Sigma receptors; Transient outward current; Whole cell patch clamp

Indexed keywords

HALOPERIDOL; POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; MALE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ELECTROPHYSIOLOGY; HALOPERIDOL; HEART VENTRICLES; MALE; MEMBRANE POTENTIALS; MODELS, STATISTICAL; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RATS; RATS, WISTAR; RECEPTORS, SIGMA;

EID: 33750006068     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.046     Document Type: Article

References (49)

1. Aimond F., Beck L., Gautier P., Chérif O.K., Davy J.M., Lorente P., Nisato D., and Vassort G. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J. Pharmacol. Exp. Ther. 292 (2000) 415-424
2. + currents in acutely isolated rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1257-1261
3. + currents in isolated adult rat ventricular myocytes. J. Gen. Physiol. 97 (1991) 973-1011
4. Arlock P., Gullberg B., and Olsson S.R. Cardiac electrophysiology of four neuroleptics: melperone, haloperidol, thioridazine and chlorpromazine. Naunyn-Schmiedeberg's Arch. Pharmacol. 304 (1978) 27-36
5. Aydar E., Palmer C.P., Klyachko V.A., and Jackson M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34 (2002) 399-410
6. Barg J., Thomas G.E., Bem W.T., Parnes M.D., Ho A.M., Belcheva M.M., McHale R.J., McLachlan J.A., Tolman K.C., Johnson F.E., et al. In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells. J. Neurochem. 63 (1994) 570-574
7. Bébarová M., Matejovič P., Pásek M., Šimurdová M., and Šimurda J. Effect of ajmaline on transient outward current in rat ventricular myocytes. Gen. Physiol. Biophys. 24 (2005) 27-45
8. + current but not the inward rectifier in rat ventricular myocytes. J. Pharmacol. Exp. Ther. 255 (1990) 1038-1046
9. + current in rat ventricle. Br. J. Pharmacol. 115 (1995) 335-343
10. + currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther. 254 (1990) 560-569
11. Eyles D.W., Stedman T.J., and Pond S.M. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 116 (1994) 161-166
12. Flanagan R.J. Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors. Ann. Clin. Biochem. 35 (1998) 261-267
13. Gallego M., and Casis O. Regulation of cardiac transient outward potassium current by norepinephrine in normal and diabetic rats. Diabetes Metab. Res. Rev. 17 (2001) 304-309
14. Hanner M., Moebius F.F., Flandorfer A., Knaus H.G., Striessnig J., Kempner E., and Glossmann H. Purification, molecular cloning and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8072-8078
15. Hassaballa H.A., and Balk R.A. Torsades de pointes associated with the administration of intravenous haloperidol. Am. J. Ther. 10 (2003) 58-60
16. Huang Z.Q., Shi G.G., Zheng J.H., and Liu B. Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and l-type calcium current. Acta Pharmacol. Sin. 24 (2003) 757-763
17. Hung C.F., Wu M.H., Tsai C.H., Chu S.H., Chi J.F., and Su M.J. Electrophysiological mechanisms for the antiarrhythmic activities of naloxone on cardiac tissues. Life Sci. 63 (1998) 1205-1219
18. Imaizumi Y., and Giles W.R. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am. J. Physiol. 253 (1987) H704-H708
19. Jann M.W., Crabtree B.L., Pitts W.M., Lam Y.W., and Carter J.G. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology 36 (1997) 32-36
20. Javaid J.I., Janicak P.G., Sharma R.P., Leach A.M., Davis J.M., and Wang Z. Prediction of haloperidol steady-state levels in plasma after a single test dose. J. Clin. Psychopharmacol. 16 (1996) 45-50
21. + channel of class III antiarrhythmic drugs?. Eur. J. Pharmacol. 241 (1993) 111-116
22. Josephson I.R., Sanchez-Chapula J., and Brown A.M. Early outward current in rat single ventricular cells. Circ. Res. 54 (1984) 157-162
23. Jourdon P., and Feuvray D. Calcium and potassium currents in ventricular myocytes isolated from diabetic rats. J. Physiol. 470 (1993) 411-429
24. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., and Ebert S.N. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 316 (2006) 1098-1106
25. + channels in rat neurohypophysial terminals requires neither G-protein nor ATP. J. Physiol. 526 (2000) 527-539
26. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
27. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43 (2004) 369-379
28. Morin-Surun M.P., Collin T., Denavit-Saubie M., Baulieu E.E., and Monnet F.P. Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8196-8199
29. Mulder H., Herder A., Wilmink F.W., Tamminga W.J., Belitser S.V., and Egberts A.C. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol. Drug Saf. 15 (2006) 107-114
30. Novakova M., Ela C., Barg J., Vogel Z., Hasin Y., and Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur. J. Pharmacol. 286 (1995) 19-30
31. 3 production in rat cardiac myocytes. Eur. J. Pharmacol. 535 (1998) 315-327
32. to phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms. J. Physiol. 569 (2005) 7-39
33. Rasty S., Amin N.B., Sabbah H.N., Mishima T., Borzak S., and Tisdale J.E. Influence of i.v. haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs. Chest 125 (2004) 1821-1829
34. + channel block by disopyramide. J. Pharmacol. Exp. Ther. 290 (1999) 515-523
35. Šimurda J., Šimurdová M., Pásek M., and Bravený P. Quantitative analysis of cardiac electrical restitution. Eur. Biophys. J. 30 (2001) 500-514
36. + channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J. Pharmacol. Exp. Ther. 269 (1994) 66-74
37. Snyders D.J., Knoth K.M., Roberds S.L., and Tamkun M.M. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol. Pharmacol. 41 (1992) 322-330
38. Sugiyama A. Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models. Nippon.Yakurigaku. Zasshi 121 (2003) 393-400
39. Sugiyama A., Satoh Y., and Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol. Appl. Pharmacol. 173 (2001) 120-128
40. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., and Moore N. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol. Appl. Pharmacol. 199 (2004) 52-60
41. Ulrich S., Neuhof S., Braun V., and Meyer F.P. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 31 (1998) 163-169
42. Van Putten T., Marder S.R., Mintz J., and Poland R.E. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry 149 (1992) 500-505
43. Volavka J., Cooper T.B., Czobor P., Lindenmayer J.P., Citrome L.L., Mohr P., and Bark N. High-dose treatment with haloperidol: the effect of dose reduction. J. Clin. Psychopharmacol. 20 (2000) 252-256
44. Wettwer E., Amos G., Gath J., Zerkowski H.R., Reidemeister J.C., and Ravens U. Transient outward current in human and rat ventricular myocytes. Cardiovasc. Res. 27 (1993) 1662-1669
45. Wettwer E., Himmel H.M., Amos G.J., Li Q., Metzger F., and Ravens U. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br. J. Pharmacol. 125 (1998) 659-666
46. + current in rat ventricle. Am. J. Physiol. 276 (1999) H1599-H1607
47. + channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J. Physiol. 517 (1999) 391-406
48. 3 cells. Neuropsychopharmacology 23 (2000) 676-689
49. Yang S.B., Proks P., Ashcroft F.M., and Rupnik M. Inhibition of ATP-sensitive potassium channels by haloperidol. Br. J. Pharmacol. 143 (2004) 960-967